MTOR and breast carcinoma: AR-C17 could inhibit the proliferation of breast cancer cells by regulating the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of the rapamycin (mTOR) signaling pathway [5].